HIGHLIGHTS
- who: Katarzyna Leszczy&nacute from the University of Texas Health Science Center at Houston, United States have published the research work: The NLRP3 inflammasome as a new target in respiratory disorders treatment, in the Journal: (JOURNAL)
- what: The review aims to describe and summarise the contribution of NLRP3 inflammasome to respiratory disorders development, including allergic rhinitis, asthma and chronic obstructive pulmonary disease (COPD).
- how: The results showed that the administration of Belnacasan into mice with OVA-induced AR inhibited the AR symptoms i.e. sneezing and scratching compared with ATP administration which overactivated . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.